Pregabalin Capsule
Product Images NDC 71335-9671

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-9671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713359671)

Label (Lbl713359671)
Each capsule of this drug, Pregabalin Capsules USP, contains 225mg of the active ingredient, labeled with the NDC number 71335-9671-1. It has been repackaged by Bryant Ranch Prepack, Inc. and should be kept out of reach of children. The drug should be stored between 20-25°C (68-77°F) with slight temperature excursions allowed. The text also suggests that this drug is only available through a pharmacist with a prescription.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The text contains a table or graph displaying the percentage of patients who have improved and the percentage improvement in pain from baseline, however, without a proper format, it is not available.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
The text is presenting a table that shows the percentage of improvement in pain from baseline in patients who took Pregabalin 160 mg for three days. The table also includes numbers such as 100, 2, 10, and some values under the columns labeled 2w, 220, 23, 20, 280, 2, 20, 2w, and 23w. It is not clear what these values represent. The text is not providing any additional useful information.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
This appears to be a medical data sheet showing different dosages of medications and their effectiveness in improving pain levels. The text mentions percentages of patients who experienced improvement with different dosages of Pregabalin and Pregabain taken multiple times a day. There is also a chart showing the percentage improvement in pain levels from baseline.*
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
This text provides a comparison of the effectiveness of different medications in relieving pain. The medications being compared are Fregabalin (at a dose of 100mg three times a day), Pregataiin (at a dose of 80mg three times a day), and a placebo. The text includes a chart that shows the percentage of patients who experienced improvement with each treatment. The chart also shows the percentage of improvement in pain from baseline for each treatment.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
This is a study report with some treatment doses listed, however, it is not possible to determine the purpose or outcome of the study. The text appears to be a table or chart, indicating potentially statistical significance of the treatment against placebo.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
This is a chart showing the percentage of patients who experienced improvement in pain from baseline after taking either Pregabalin at a daily dose of 300mg or 450mg, or a placebo. The chart ranges from 0 to 100% improvement and shows increments of 10. There are no further details available.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a table showing the Estimated Percentage of Subjects without LTR (unknown what LTR stands for) along with the number of days and treatment arms labeled "Progabain" and "Placebo." The percentage values are evenly distributed from 0% to 100% in intervals of 10%. There is no further context available.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
The text appears to be a table showing the percentage of subjects improved on Pregabalin and Placebo drugs from baseline to week 16 BOCF. The percentage of subjects improved is given in the range of 100 to 280.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text seems to be a calculation used in medical practice to estimate an adult patient's creatinine clearance (CLCT) based on their age, weight, and serum creatinine level. The formula requires the patient's age in years and weight in kilograms to be multiplied together, and that product is then multiplied by a constant of either 0.85 or 1 depending on their gender. The result is then multiplied by the patient's serum creatinine level measured in milligrams per deciliter (mg/dL) and divided by 72 to obtain an estimate of their creatinine clearance.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.